AroCell has announced a public offer to the shareholders of IDL to sell all their shares in IDL in exchange for new shares in AroCell. The total value of the offer amounts to approximately SEK 237 million. AroCell’s shares are admitted to trading on Nasdaq First North Growth Market and IDL’s on Spotlight Next. Wigge & Partners acts as legal advisor to AroCell in the public offer.
AroCell AB (publ) is a Swedish company that develops standardized modern blood tests to support treatment, prognosis and follow-up of cancer patients. AroCell’s technology is based on patented methods for measuring the protein concentration of Thymidine kinase 1 (TK1) in blood samples. The TK 210 ELISA test provides valuable information that will be able to help clinics optimize treatment strategies and forecast the risk of recurrent tumor disease when monitoring and following up the patient.
IDL Biotech AB (publ) is a Swedish biotechnology company, specialized in the field of in vitro diagnostics within oncology and bacteriology. The company develops, produces and markets unique and cost-effective products for medically important indications and has an established international distributor network.
The offer values IDL at approximately SEK 237 million. The offer was announced on 10 May 2021 and the acceptance period for the offer is expected to be between 5 June and 28 June 2021.
The advisory team consisted of Peter Bäärnhielm (Partner), Henrik Fritz (Partner), Emma Brolund (Senior Associate) and Fredrik Arvebratt (Associate).
